interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Tirofiban Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Tirofiban Hydrochloride, and who makes it?

Tirofiban Hydrochloride appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 3 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 22.9 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Tirofiban Hydrochloride3 dosage-form groups in the Orange Book
3generic makers listed
  1. Tirofiban Hydrochloride appears in 3 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 3 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 22.9 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Intravenous

One to three generic makers listed

Brand listed as marketed: Aggrastat. 3 generic makers with 5 generic products listed as marketed; the first generic approval is dated 8 April 2021.

1995200020052010201520202025203003brand 1998Gland Pharma Ltd, first approval 8 April 2021Nexus Pharmaceuticals Llc, first approval 7 February 2023Eugia Pharma Specialities Ltd, first approval 1 May 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Gland Pharma Ltd8 April 20211
Nexus Pharmaceuticals Llc7 February 20232
Eugia Pharma Specialities Ltd1 May 20232

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Injectable, Injection

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

1995200020052010201520202025203001brand 1998data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Injection

Brand listed, no generic listed as marketed

Brand listed as marketed: Aggrastat. No generic is listed as marketed.

201520202025203001brand 2016data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.